Posted by Michael Wonder on 02 Jun 2018
Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab
1 June 2018 - Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology.
Sandoz, a Novartis division and the global leader in biosimilars, today announced that the CHMP of the EMA has adopted a positive opinion for marketing authorisation of a proposed biosimilar adalimumab.
The CHMP opinion recommends the proposed Sandoz biosimilar adalimumab for treatment of all indications of its reference medicine including rheumatoid arthritis, plaque psoriasis, Crohn's disease and ulcerative colitis.
